Systemic immune-inflammation index may be used to predict the development of colorectal cancer from colonic polyps.

IF 2.6 4区医学 Q2 ONCOLOGY

Future oncology Pub Date : 2026-05-01 Epub Date: 2026-03-19 DOI:10.1080/14796694.2025.2609975

Ying Chun, Jing Xia, Chaosheng Peng

{"title":"Systemic immune-inflammation index may be used to predict the development of colorectal cancer from colonic polyps.","authors":"Ying Chun, Jing Xia, Chaosheng Peng","doi":"10.1080/14796694.2025.2609975","DOIUrl":null,"url":null,"abstract":"Aims: This study aims to assess whether the Systemic Immune-Inflammation Index (SII) can serve as a predictive biomarker for the progression of colonic polyps to colorectal cancer (CRC).Patients & methods: A total of 351 individuals (236 with colonic polyps and 115 with CRC) who underwent colonoscopy and received a pathological diagnosis at The Six Medical Center of PLA General Hospital were included. Demographic, clinical, and laboratory data were collected. SII was calculated using neutrophil, monocyte, and lymphocyte counts. Statistical analyses, including univariate and multivariate logistic regression, identified risk factors for CRC development, and receiver operating characteristic (ROC) curves were used to assess the diagnostic performance of SII and CEA.Results: SII was significantly higher in CRC patients compared to those with colonic polyps (P < 0.001). Univariate and multivariate analyses revealed that SII, CEA, and lymphocyte count were independent predictors of CRC. ROC analysis showed that SII had a good diagnostic performance with an AUC of 0.823, sensitivity of 80.9%, and specificity of 72.0%.Conclusions: SII is a promising, noninvasive biomarker for identifying patients at increased risk of CRC among those with colonic polyps. Further prospective studies are needed to confirm these findings.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1321-1329"},"PeriodicalIF":2.6000,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14796694.2025.2609975","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/3/19 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Aims: This study aims to assess whether the Systemic Immune-Inflammation Index (SII) can serve as a predictive biomarker for the progression of colonic polyps to colorectal cancer (CRC).

Patients & methods: A total of 351 individuals (236 with colonic polyps and 115 with CRC) who underwent colonoscopy and received a pathological diagnosis at The Six Medical Center of PLA General Hospital were included. Demographic, clinical, and laboratory data were collected. SII was calculated using neutrophil, monocyte, and lymphocyte counts. Statistical analyses, including univariate and multivariate logistic regression, identified risk factors for CRC development, and receiver operating characteristic (ROC) curves were used to assess the diagnostic performance of SII and CEA.

Results: SII was significantly higher in CRC patients compared to those with colonic polyps (P < 0.001). Univariate and multivariate analyses revealed that SII, CEA, and lymphocyte count were independent predictors of CRC. ROC analysis showed that SII had a good diagnostic performance with an AUC of 0.823, sensitivity of 80.9%, and specificity of 72.0%.

Conclusions: SII is a promising, noninvasive biomarker for identifying patients at increased risk of CRC among those with colonic polyps. Further prospective studies are needed to confirm these findings.

查看原文本刊更多论文

系统免疫炎症指数可用于预测结肠息肉的发展。

目的：本研究旨在评估系统性免疫炎症指数（SII）是否可以作为结肠息肉向结直肠癌（CRC）发展的预测性生物标志物。患者与方法：在解放军总医院第六医疗中心行结肠镜检查并病理诊断的351例患者（结肠息肉236例，结直肠癌115例）。收集了人口统计学、临床和实验室数据。SII通过中性粒细胞、单核细胞和淋巴细胞计数计算。统计分析，包括单变量和多变量logistic回归，确定了CRC发展的危险因素，并使用受试者工作特征（ROC）曲线评估SII和CEA的诊断效果。结论：SII是一种有希望的、无创的生物标志物，可用于识别结肠息肉患者中CRC风险增加的患者。需要进一步的前瞻性研究来证实这些发现。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Future oncology ONCOLOGY-

CiteScore

5.40

自引率

3.00%

发文量

335

审稿时长

4-8 weeks

期刊介绍： Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community. The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.